Last reviewed · How we verify
Fragmin (BEMIPARIN)
Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade.
Fragmin (Bemiparin) is a low molecular weight heparin, a small molecule drug class, originally developed and currently owned by Pfizer Inc. It was FDA approved in 1994 for the treatment of deep venous thrombosis and pulmonary embolism. Fragmin works by inhibiting the coagulation cascade, specifically by binding to and activating antithrombin, which in turn inhibits thrombin and factor Xa. As a commercial product, Fragmin is still patented, and its generic status is unknown. Key safety considerations include the risk of bleeding and heparin-induced thrombocytopenia.
At a glance
| Generic name | BEMIPARIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | Low Molecular Weight Heparin |
| Target | Factor Xa and thrombin (via antithrombin III enhancement) |
| Modality | Oligosaccharide |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
| First approval | 1994 |
Mechanism of action
Dalteparin is low molecular weight heparin with antithrombotic properties. It acts by enhancing the inhibition of Factor Xa and thrombin by antithrombin. In humans, dalteparin potentiates preferentially the inhibition of coagulation Factor Xa, while only slightly affecting the activated partial thromboplastin time (APTT).
Approved indications
- Deep venous thrombosis
- Pulmonary embolism
Common side effects
- Major Bleeding Reactions
- Postoperative Transfusions
- Wound Hematoma
- Injection Site Hematoma
- Hematuria
- Hemorrhage
- Hematoma at the injection site
- Pain at the injection site
- Transient elevation of transaminases
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin (PHASE3)
- Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients (NA)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fragmin CI brief — competitive landscape report
- Fragmin updates RSS · CI watch RSS
- Pfizer portfolio CI